News

The Company expects to enter the clinic in Q4 2017, pending the regulatory approval to conduct the clinical trial which is expected shortly. These indolent and rare hormone

The manufacturing license follows an inspection by the Spanish Medicines Agency (AEMPS), and provides production capacity for the potential initial European commercial roll out of Cx601, an investigational

The Swiss pharma major has reported positive topline results from the study, which assessed the safety and efficacy of oral once-daily fingolimod in children and adolescents (ages 10 to

“We are very excited to dose the first patient and initiate the Phase 2 trial of AG013 for oral mucositis, one of the most common and debilitating complications

Dasotraline’s pharmacokinetic properties, such as an extended half-life, and clinical study findings support its potential for sustained control of ADHD symptoms over the 24-hour dosing interval with once-daily

The deal will also see the Canadian firm sell certain rights to plasma products and technology to the joint venture pertained to the Chinese market. The acquisition will

The approval will allow Pfizer to treat adults and children two years and older with relapsed or refractory CD33-positive AML with Mylotarg. Mylotarg is an antibody-drug conjugate that

Under the terms of a definitive purchase agreement executed by the companies, Saol Therapeutics will acquire the three hyperimmune products currently marketed by Aptevo:  WinRho SDF for autoimmune

The findings, made by researchers at the University of Pittsburgh Center for Vaccine Research and National Institutes of Health, also show that an experimental drug may hold promise